Interview – Kura’s combo test nears
Can a combination approach improve the efficacy of ziftomenib in AML patients with KMT2A rearrangements?
ASH 2023 – J&J makes menin a three-horse race
But JNJ-75276617 still has much to prove.
The menin fault lines emerge
With revumenib’s broader coverage Syndax tries to gain ground on Kura’s ziftomenib, but hits a new snag.
